Study guide
10.5 Anemia and Transfusion Management in Cardiac Patients
AACN Cardiac Medicine Certification CMC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview and the CMC Test Plan
1.1 CMC Exam Format, Eligibility, Fees & Scoring 1.2 The CMC Test Plan: Four Domains and How to Study Them
2 Chapter 2: Acute Coronary Syndromes and Ischemic Heart Disease
2.1 Pathophysiology & Classification of Acute Coronary Syndromes 2.2 12-Lead ECG Localization & Cardiac Biomarker Trajectories 2.3 Acute Reperfusion Strategies & Nursing Management 2.4 Complications of Acute Myocardial Infarction 2.5 Chronic Coronary Disease, Hyperlipidemia and Lipid-Lowering Therapy
3 Chapter 3: Heart Failure, Cardiomyopathies, Pericardial and Valvular Disease
3.1 Acute Decompensated Heart Failure & Staging 3.2 Acute Cardiogenic Pulmonary Edema 3.3 Dilated, Hypertrophic, and Restrictive Cardiomyopathies 3.4 Acute Pericarditis, Cardiac Tamponade & Constrictive Pericarditis 3.5 Infective Endocarditis, Myocarditis and Rheumatic Heart Disease 3.6 Valvular Heart Disease: Stenosis & Regurgitation 3.7 Syncope: Cardiac Versus Non-Cardiac Causes and Workup
4 Chapter 4: Dysrhythmias, Conduction Disorders and Electrophysiologic Interventions
4.1 Atrial Fibrillation, Atrial Flutter & Supraventricular Tachycardias 4.2 Ventricular Arrhythmias & Cardiac Arrest Management 4.3 Atrioventricular Blocks & Intraventricular Conduction Delays 4.4 Temporary Pacing: Transcutaneous, Transvenous and Epicardial 4.5 Permanent Pacemakers, CRT and Device Troubleshooting 4.6 Implantable and Wearable Cardioverter Defibrillators 4.7 Catheter Ablation and Post-Ablation Nursing Care 4.8 Synchronized Cardioversion and Defibrillation
5 Chapter 5: Vascular Conditions and Vascular Interventions
5.1 Aortic Dissection, Aortic Aneurysms & Hypertensive Crises 5.2 Peripheral Artery Disease & Acute Limb Ischemia 5.3 Acute Venous Thrombosis, DVT and VTE Prophylaxis 5.4 Peripheral and Carotid Angiography and Interventions 5.5 Endovascular Aortic Repair: EVAR and TEVAR 5.6 Catheter-Directed Thrombolysis and Post-Intervention Vascular Complications
6 Chapter 6: Shock States and Mechanical Circulatory Support
6.1 Cardiogenic Shock Pathophysiology, Hemodynamics & Etiologies 6.2 Non-Cardiogenic Shock: Hypovolemic, Distributive and Obstructive 6.3 Multisystem Organ Dysfunction Syndrome 6.4 Intra-Aortic Balloon Pump Therapy & Waveform Optimization 6.5 Percutaneous & Surgical Mechanical Circulatory Support: Impella, VA-ECMO, LVAD
7 Chapter 7: Cardiac Procedures and Structural Heart Interventions
7.1 Diagnostic Cardiac Catheterization & Coronary Angiography Interpretation 7.2 Percutaneous Coronary Intervention: Stents, No-Reflow and Post-PCI Care 7.3 Structural Heart Interventions: TAVR, MitraClip, Pericardiocentesis 7.4 Post-Cardiac Surgery Management (>48 Hours) & Late Complications
8 Chapter 8: Cardiovascular Pharmacology
8.1 Inotropes, Vasopressors & Inodilators 8.2 Vasodilators & Antianginal Agents 8.3 Antiarrhythmic Agents: Vaughan Williams Classes I-IV 8.4 Anticoagulants, Antiplatelets, Thrombolytics & Reversal Agents 8.5 Diuretics and Decongestion Strategies 8.6 Guideline-Directed Medical Therapy for Heart Failure
9 Chapter 9: Non-Cardiovascular Conditions: Pulmonary
9.1 Acute Pulmonary Embolism 9.2 Acute Respiratory Failure and ARDS 9.3 Pleural Space Abnormalities: Pneumothorax, Effusion and Hemothorax 9.4 Pulmonary Hypertension and Right Ventricular Failure 9.5 Sleep-Disordered Breathing in Cardiac Patients
10 Chapter 10: Non-Cardiovascular Conditions: Endocrine, Renal, Hematologic, Neurologic and Behavioral
10.1 Diabetes Mellitus and Glycemic Control in Cardiac Care 10.2 Thyroid and Adrenal Disorders in the Cardiac Patient 10.3 Metabolic Syndrome and Cardiometabolic Risk 10.4 Coagulopathies: Heparin-Induced Thrombocytopenia, DIC and Bleeding Disorders 10.5 Anemia and Transfusion Management in Cardiac Patients 10.6 Acute Ischemic and Hemorrhagic Stroke in the Cardiac Patient 10.7 Acute Kidney Injury and Contrast-Associated Nephropathy 10.8 Chronic Kidney Disease and the Dialysis-Dependent Cardiac Patient 10.9 Electrolyte Imbalances and Dysrhythmia Risk 10.10 Substance Use, Withdrawal and Cardiac Effects 10.11 Non-Cardiac Chest Pain: Differential and Triage 10.12 Non-Cardiovascular Multisystem Complications in Cardiac Patients
11 Chapter 11: Monitoring and Diagnostics
11.1 Pulmonary Artery Catheterization & Hemodynamic Waveform Interpretation 11.2 Arterial Line Monitoring, Continuous Cardiac Output & ScvO2 11.3 Echocardiography, Cardiac MRI & Non-Invasive Cardiac Imaging 11.4 Stress Testing and Myocardial Perfusion Imaging 11.5 Remote Cardiovascular Monitoring and Ambulatory Rhythm Devices 11.6 Laboratory Testing in Cardiac Care 11.7 Arterial Blood Gases and Acid-Base Interpretation 11.8 Pulse Oximetry, Capnography and Chest Radiography
12 Chapter 12: Respiratory, Renal and Multisystem Therapeutic Interventions
12.1 Non-Invasive Ventilation in Cardiac Patients 12.2 Invasive Mechanical Ventilation and Heart-Lung Interactions 12.3 Renal Replacement Therapy: Hemodialysis, CRRT, SCUF and Ultrafiltration 12.4 Targeted Temperature Management After Cardiac Arrest 12.5 Palliative and End-of-Life Care in Advanced Cardiac Disease
10.5 Anemia and Transfusion Management in Cardiac Patients
Key Takeaways Explain This Topic AI
The myocardium extracts 60-75% of delivered oxygen at rest versus about 25% for the body as a whole, so it can only compensate for anemia by increasing coronary flow - which a fixed stenosis prevents, making anemia a direct trigger for type 2 MI.
Iron deficiency in heart failure is ferritin below 100 ng/mL, or ferritin 100-299 ng/mL with transferrin saturation below 20%; IV ferric carboxymaltose or ferric derisomaltose improves symptoms while oral iron is largely ineffective (IRONOUT-HF).
Restrictive transfusion at 7 g/dL applies to stable general critical illness; AABB 2023 recommends 8 g/dL with pre-existing cardiovascular disease, and MINT reported 16.9% versus 14.5% events favoring a liberal 10 g/dL target in acute MI (P = 0.07, not significant).
TACO is hypertensive volume overload with elevated filling pressures and BNP that responds to diuresis; TRALI is a permeability injury within 6 hours with normal filling pressures that is worsened by diuretics.
In a continuous-flow LVAD patient, LDH above about 3 times the upper limit of normal with plasma-free hemoglobin above 20-40 mg/dL, tea-colored urine, and rising pump power signals pump thrombosis and is a device emergency.
Last updated: August 2026
Why Anemia Is a Cardiac Problem, Not Just a Lab Value
Oxygen delivery is the product of cardiac output and arterial oxygen content:
DO2 = CO x CaO2 x 10 , where CaO2 = (1.34 x Hgb x SaO2) + (0.003 x PaO2)
Hemoglobin dominates that equation. At a normal cardiac output of 5 L/min, a hemoglobin of 15 g/dL and a saturation of 100 percent, delivery is roughly 1,000 mL/min against a whole-body consumption of about 250 mL/min — an extraction ratio near 25 percent. Halving hemoglobin halves delivery. Dissolved oxygen (the 0.003 x PaO2 term) is trivial, which is why raising the FiO2 in an anemic patient with a normal saturation accomplishes almost nothing.
The myocardium is the organ that cannot compensate. Unlike skeletal muscle or splanchnic beds, which extract about 25 percent of delivered oxygen at rest and can extract far more under stress, the heart extracts 60 to 75 percent at rest . Its extraction reserve is nearly exhausted before anything goes wrong. The only way the myocardium can increase oxygen supply is to increase coronary blood flow . Two things then follow:
With a fixed epicardial stenosis, coronary flow reserve is limited, so anemia translates directly into subendocardial ischemia — the subendocardium is perfused last, during diastole, at the lowest perfusion pressure.
Anemia produces compensatory tachycardia , which shortens diastole and therefore shortens the coronary perfusion window, and increases stroke volume and cardiac output, which raises wall stress and myocardial oxygen demand. The compensation worsens the problem.
This is the physiology behind type 2 myocardial infarction : troponin elevation from supply-demand mismatch without plaque rupture. Anemia sits alongside tachyarrhythmia, hypotension, sepsis, severe hypertension, and hypoxemia on the standard list of triggers. The nursing implication is that the intervention is correcting the trigger, not reflex catheterization.
Anemia is present in 30 to 50 percent of heart failure patients and is an independent predictor of mortality, hospitalization, and reduced functional capacity. Iron deficiency is present in roughly half of heart failure patients even when hemoglobin is normal , and it impairs skeletal and cardiac muscle oxidative metabolism independently of the red cell mass.
Causes in the cardiac patient
Cause Recognition
Iatrogenic phlebotomy 40-70 mL of blood per ICU day between labs and arterial line discard volume; a week of routine draws costs a unit of blood
GI bleeding on antithrombotics Dual antiplatelet therapy, anticoagulant, or triple therapy; falling hemoglobin with melena or occult blood; highest risk with triple therapy
Heyde syndrome Severe aortic stenosis plus GI angiodysplasia plus acquired von Willebrand syndrome; normal coagulation screen
Mechanical hemolysis Prosthetic valve, especially with paravalvular leak; continuous-flow LVAD pump thrombosis; ECMO and intra-aortic balloon pump
Anemia of chronic disease/inflammation Hepcidin-mediated iron sequestration: low serum iron, low total iron-binding capacity, normal or high ferritin, low transferrin saturation
CKD Erythropoietin deficiency; normocytic normochromic anemia proportional to declining eGFR
Absolute iron deficiency Microcytic, low ferritin, high total iron-binding capacity, low transferrin saturation, high red cell distribution width
Dilutional pseudoanemia Congestion in acute decompensated heart failure; hemoglobin rises with effective diuresis without any blood being made
Hemolysis surveillance in device patients deserves its own emphasis because it is a recurring CMC item. In a continuous-flow LVAD recipient, suspect pump thrombosis when lactate dehydrogenase (LDH) rises above about 3 times the upper limit of normal (commonly quoted as above 600 to 800 IU/L), plasma-free hemoglobin exceeds 20 to 40 mg/dL , haptoglobin falls, schistocytes appear on the smear, the urine turns tea-colored or cola-colored, and pump power or watts trend upward with worsening heart failure symptoms and low pulsatility index. Escalate immediately: this is a device emergency, not a hematology consult.
Iron Deficiency and Its Treatment in Heart Failure
Iron deficiency in heart failure has its own definition , and it is not the general medicine definition:
- Absolute iron deficiency: ferritin below 100 ng/mL
- Functional iron deficiency: ferritin 100 to 299 ng/mL with a transferrin saturation (TSAT) below 20 percent
The functional category exists because ferritin is an acute-phase reactant. In an inflamed heart failure patient, iron can be sequestered in the reticuloendothelial system by hepcidin while ferritin looks reassuring — the iron is present but unavailable. Always interpret ferritin together with TSAT.
Intravenous iron works; oral iron largely does not. Hepcidin blocks enteral absorption in inflammatory states, and the IRONOUT-HF trial showed that high-dose oral iron polysaccharide failed to improve peak oxygen consumption or meaningfully replete iron stores. In contrast, ferric carboxymaltose improved symptoms, functional class, 6-minute walk distance, and quality of life in FAIR-HF and CONFIRM-HF; AFFIRM-AHF showed a reduction in heart failure hospitalizations after an acute admission; and ferric derisomaltose showed consistent effects in IRONMAN. The 2022 AHA/ACC/HFSA heart failure guideline supports IV iron for patients with NYHA class II to III HFrEF and iron deficiency to improve functional status and quality of life. Typical dosing is ferric carboxymaltose 750 mg on two occasions at least 7 days apart, or weight- and hemoglobin-based Ganzoni dosing.
Nursing points for IV iron: monitor for hypersensitivity during and for at least 30 minutes after the infusion, expect transient hypophosphatemia with ferric carboxymaltose (check phosphate if the patient develops new weakness or bone pain), and know that recheck of iron studies is deferred at least 4 to 8 weeks because levels are artificially elevated immediately after administration.
Erythropoiesis-stimulating agents (ESAs) are the cautionary tale. In RED-HF, darbepoetin alfa raised hemoglobin in heart failure patients without improving outcomes and increased thromboembolic events. In CKD trials (CHOIR, TREAT), targeting a normal hemoglobin increased stroke, thrombosis, and death compared with a partial-correction strategy. Current practice targets hemoglobin around 10 to 11 g/dL in CKD and does not normalize it, and ESAs have no established role in heart failure anemia.
Transfusion Thresholds: the Cardiac Exception
The general critical-care rule is a restrictive threshold of 7 g/dL , established by TRICC in general ICU patients and supported by TRISS in septic shock and by trials in upper GI bleeding. Restrictive strategies reduce transfusion volume without increasing mortality, and they avoid the immunomodulatory, volume, and infectious hazards of transfusion.
The cardiac patient is the classic exception to that rule , and CMC candidates should be able to defend a higher threshold with specifics:
- Population Threshold
- Hemodynamically stable general critical illness 7 g/dL
Pre-existing cardiovascular disease, or orthopedic surgery 8 g/dL (AABB 2023; the same guideline suggests 7.5 g/dL for cardiac surgery)
Cardiac surgery, intraoperative and postoperative Restrictive 7.5 g/dL was non-inferior to 9.5 g/dL in TRICS III
Acute myocardial infarction with anemia Practice is shifting toward a more liberal threshold near 10 g/dL based on the MINT trial signal
Active hemorrhage or symptomatic anemia at any hemoglobin Transfuse for physiology, not for a number
The MINT trial (2023) randomized 3,504 patients with myocardial infarction and anemia to a restrictive strategy (transfuse at 7 to 8 g/dL) versus a liberal strategy (maintain hemoglobin at or above 10 g/dL). The primary composite of recurrent MI or death at 30 days occurred in 16.9 percent of the restrictive group versus 14.5 percent of the liberal group (risk ratio about 1.15, P = 0.07) — the difference did not reach statistical significance, but every point estimate, including cardiac death, favored the liberal strategy. The correct exam-level statement is that MINT did not prove superiority but its signal, combined with the physiology of near-maximal myocardial oxygen extraction, is why many institutions now use a threshold of 8 to 10 g/dL in acute MI rather than 7.
Operationally: transfuse one unit at a time and reassess . One unit of packed red cells raises hemoglobin by about 1 g/dL (hematocrit about 3 percent) in a non-bleeding adult. Assess symptoms, heart rate, lactate, ST segments, and mixed venous or central venous oxygen saturation rather than chasing a target number.
Transfusion Reactions
Reaction Timing and features Immediate nursing action
Acute hemolytic (ABO incompatibility) Minutes; fever, chills, flank or back pain, hypotension, dark or red urine, oozing from IV sites from DIC, sense of impending doom Stop immediately. Maintain the line with 0.9% NaCl through new tubing , notify provider and blood bank, re-verify all identifiers, send blood and urine samples with the bag and tubing, support blood pressure, maintain urine output
Febrile non-hemolytic 1-6 hours; temperature rise of 1 degree Celsius or more with chills, no hemolysis Stop, rule out hemolysis and bacterial contamination, give acetaminophen; prevent with leukoreduced products
Allergic / urticarial Minutes to hours; hives and itching only Pause, give an antihistamine, may resume cautiously if symptoms resolve and there is no systemic involvement
Anaphylactic Immediate; hypotension, bronchospasm, angioedema, shock; classically IgA deficiency with anti-IgA antibodies Stop permanently, epinephrine 0.3-0.5 mg IM , airway and fluid support; future transfusions require washed or IgA-deficient products
TRALI Within 6 hours ; acute hypoxemia, bilateral pulmonary infiltrates, often fever and transient leukopenia; normal filling pressures Stop, support oxygenation with lung-protective ventilation, do not diurese , report to blood bank for donor investigation
TACO Within 6-12 hours; dyspnea, orthopnea, hypertension , jugular venous distension, S3, positive fluid balance Stop or slow, sit the patient upright, give oxygen, administer a diuretic, obtain BNP and chest radiograph
Delayed hemolytic 3-14 days; unexplained fall in hemoglobin, mild jaundice, positive direct antiglobulin test; anamnestic response to minor antigens such as Kidd or Rh Notify blood bank for antibody identification and future antigen-negative units; monitor hemoglobin and renal function
Bacterial contamination / septic Minutes to hours; high fever, rigors, hypotension, vomiting; platelets carry the highest risk because they are stored at room temperature Stop, culture the patient and the bag, start broad-spectrum antibiotics, provide hemodynamic support
TRALI versus TACO
This distinction is a guaranteed exam item because the treatments are opposite: TACO needs diuresis, TRALI is worsened by it.
Feature TRALI (transfusion-related acute lung injury) TACO (transfusion-associated circulatory overload)
Mechanism Donor anti-HLA/anti-HNA antibodies prime neutrophils; non-cardiogenic permeability injury Hydrostatic volume overload exceeding cardiac reserve
Onset Within 6 hours , often during or shortly after the transfusion Within 6-12 hours , often after rapid or large-volume infusion
- Blood pressure Normal or hypotensive Hypertensive
- Jugular veins / S3 Normal, no S3 Distended, S3 present
- Filling pressures Normal - CVP and PAOP not elevated (PAOP 18 mm Hg or less) Elevated CVP and PAOP
- BNP / NT-proBNP Normal or unchanged Elevated , often a post-to-pre ratio above 1.5
- Fever / leukopenia Common, transient leukopenia typical Absent
Chest radiograph Bilateral infiltrates with a normal-sized heart Bilateral infiltrates with cardiomegaly and vascular redistribution
Response to diuretics No improvement , may worsen Prompt improvement
Treatment Supportive oxygenation, lung-protective ventilation, avoid diuresis Diuresis, upright positioning, slower or divided future transfusions
Risk factors for TACO are precisely the CMC population: pre-existing heart failure, renal failure, age over 70, a positive fluid balance, and rapid infusion. Prevention is straightforward and is entirely nursing-controlled — one unit at a time infused over 2 to 4 hours (never exceeding 4 hours), a pre-transfusion diuretic in patients with reduced ejection fraction, and reassessment before ordering the next unit.
Massive transfusion considerations
In large-volume resuscitation, use a balanced 1:1:1 ratio of red cells, plasma, and platelets, and anticipate citrate toxicity — citrate chelates calcium, producing ionized hypocalcemia with hypotension, prolonged QT interval, and impaired coagulation. Treat with calcium chloride 1 g or calcium gluconate 2 to 3 g IV, guided by ionized calcium. Also anticipate hyperkalemia from stored cells (relevant in renal failure and in rapid central infusion), hypothermia (use a fluid warmer), and dilutional coagulopathy.
Patient Blood Management
The cheapest unit of blood is the one never lost. Nursing-driven blood conservation includes:
Small-volume ("pediatric") collection tubes and closed inline arterial-line sampling systems that return the discard volume, which together can cut iatrogenic loss substantially
Bundling laboratory draws, eliminating standing daily orders that no longer change management, and using point-of-care testing where appropriate
Intraoperative cell salvage and retrograde autologous priming in cardiac surgery
Tranexamic acid as an antifibrinolytic in cardiac surgery and trauma, reducing transfusion requirements; note the dose-related risk of seizure at high doses
Preoperative anemia identification and treatment with IV iron in an anemia clinic rather than transfusion on the day of surgery
- Adherence to restrictive thresholds where they apply, and single-unit ordering with reassessment
- Safe administration essentials
Two qualified staff verify patient identifiers, blood type, unit number, and expiration at the bedside. Blood must be started within 30 minutes of release from the blood bank and completed within 4 hours. Use a filtered administration set and 0.9% sodium chloride only — lactated Ringer's contains calcium that can clot the unit, and dextrose solutions cause hemolysis. Take a full set of vital signs before starting, remain with the patient for the first 15 minutes when most severe reactions declare themselves, recheck vital signs at 15 minutes and per policy thereafter, and never infuse medications through the same lumen.